|
|
|
| Expression and Clinical Significance of LncRNA MNX-AS1 in Non-Small Cell Lung Cancer |
| LIU Gaofeng, ZHANG Yong, ZHANG Xiaozhen, et al |
| The 988th Hospital of PLA Joint Logistics Support, Henan Zhengzhou 450042, China |
|
|
|
|
Abstract Objective: To investigate the expression and clinical significance of long non-coding RNA (lncRNA) MNX1-AS1 in non-small cell lung cancer (NSCLC). Methods: The primary lesions and adjacent tissues of 180 patients with NSCLC from Jun.2015 to Jun.2017,diagnosed by histopathology and surgically removed,were collected. Real time quantitative PCR (RT-qPCR) was used to detect the expression of MNX1-AS1. The relationship between the expression of MNX1-AS1 and the clinicopathological characteristics of NSCLC patients was analyzed. Kaplan-Meier method and Cox regression analysis were used to analyze the prognosis of patients with different expression levels of MNX1-AS1. Results: The relative expression of MNX1-AS1 in NSCLC tissues was significantly higher than that in adjacent tissues (P<0.001). The expression of MNX1-AS1 was significantly correlated with tumor differentiation,TNM stage and lymph node metastasis in NSCLC patients. The progression free survival,overall survival and 5-year overall survival rate of patients with high expression of MNX1-AS1 were lower than those of patients with low expression of MNX1-AS1 (P<0.05). Multivariate Cox regression analysis showed that MNX1-AS1 level was an independent prognostic factor in NSCLC patients. Conclusion: MNX1-AS1 was highly expressed in NSCLC and was closely related to its pathological characteristics and prognosis. It might be a new biomarker for early diagnosis and prognosis evaluation of NSCLC patients.
|
|
|
|
|
|
[1] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer Clin,2018,68(6):394~424.
[2] Siegel RL,Miller KD,Jemal A.Cancer statistics,2019[J]. CA Cancer Clin,2019,69(1):7~34.
[3] Heist RS.First-line systemic therapy for non-small cell lung cancer[J]. Hematol Oncol Clin North Am,2017,31(1):59~70.
[4] 迟春天,鲍永霞,周建,等.长链非编码RNA在癌症中的研究进展[J].中华老年多器官疾病杂志,2018(5):389~393.
[5] Ji D,Wang Y,Sun B,et al.Long non-coding RNA MNX1-AS1 promotes hepatocellular carcinoma proliferation and invasion through targeting miR-218-5p/COMMD8 axis[J]. Biochem Biophys Res Commun,2019,513(3):669~674.
[6] Gao Y,Xu Y,Wang J,et al.lncRNA MNX1-AS1 promotes glioblastoma progression through inhibition of miR-4443[J]. Oncol Res,2019,27(3):341~347.
[7] Martin-Fernandez ML,Clarke DT,Roberts SK,et al.Structure and dynamics of the EGF receptor as revealed by experiments and simulations and its relevance to non-small cell lung cancer[J]. Cells,2019,8(4):316.
[8] 张亚琛,梁迪,靳晶,等.非小细胞肺癌相关lncRNA的研究进展[J].中国肺癌杂志,2018,21(1):43~49.
[9] Li AH,Zhang HH.Overexpression of lncRNA MNX1-AS1 is associated with poor clinical outcome in epithelial ovarian cancer[J].Eur Rev Med Pharmacol Sci,2017,21(24):5618~5623.
[10] Liu X,Yang Q,Yan J,et al.LncRNA MNX1-AS1 promotes the progression of cervical cancer through activating MAPK pathway[J].Cell Biochem,2019,120(3):4268~4277.
[11] Liu H,Han L,Liu Z,et al.Long noncoding RNA MNX1-AS1 contributes to lung cancer progression through the miR-527/BRF2 pathway[J].Cell Physiol,2019,234(8):13843~13850.
[12] Zhang W,Huang L,Lu X,et al.Upregulated expression of MNX1-AS1 long noncoding RNA predicts poor prognosis in gastric cancer[J]. Bosn Basic Med Sci,2019,19(2):164~171. |
|
|
|
2021, Vol. 27 
